Adverse reactions and management in Endostar combined with concurrent chemoradiotherapy for inoperable stage Ⅲ non-small cell lung cancer

Objective To observe the adverse reactions of recombinant human endostatin(Endostar) combined with chemoradiotherapy in the treatment of unresectable stage Ⅲ non-small cell lung cancer,and to provide theoretical basis for the new treatment. Methods The clinical data of 23 patients with inoperable locally advanced non-small cell lung cancer in our hospital from November,2013 to January,2015 were reviewed.The patients received Endostar[7.5 mg/(m²·d)] by 5 days continuous infusion at weeks 1,3,5,and 7,while two cycles of etoposide(50 mg/m²) at d₁ to d₅ and cisplatin (50 mg/m²) at d₁ and d₈ were administered at weeks 2 and 6 with concurrent three-dimensional conformal or intensity modulated conformal radiotherapy to a dose of 60-66 Gy.Toxicity was evaluated according to CTCAE 3.0. Nursing care and intervention were given when necessary during radiotherapy and chemotherapy. Results The treatment and clinical evaluation were conducted in all 23 patients,the main adverse reactions included low white blood cell count in 14 cases(grade 3 and 4,60.9%),anemia in 4 cases(grade 3 and 4,17.4%),low blood platelet count in 8 cases(grade 3 and 4,34.8%),radiation pneumonia in 1 case(grade 1,4.3%),radiation esophagitis in 1 case(grade 3,4.3%),hypotension in 6 cases(26.1%),and arrhythmia in 1 case(4.3%).There were no renal disorder,bleeding or coagulation disorders,and treatment-related death. Conclusion Endostatin infusion administration can improve the compliance of patients.The short term outcome and tolerability of Endostar combined with concurrent chemoradiotherapy for unresectable stage Ⅲ non-small cell lung cancer are good,it can reduce the toxicity,increase compliance and improve quality of life of patients.